Septerna

IPO

Pioneering a new era of GPCR drug discovery

Public · South San Francisco, United States · Founded 2022 · $250.0M raised

Employees
51–200
Founded
2022
Business Model
B2B
Total Funding
$250.0M
Last Round
$150.0M Series BJul 2023
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Septerna is a biotechnology company powered by its proprietary Native Complex Platform, designed to unlock the full potential of G protein-coupled receptors (GPCRs) — the most prolific drug target class. The company is building a deep pipeline of oral small molecule product candidates across three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Co-founded by Nobel laureate Robert Lefkowitz and CEO Jeffrey Finer, Septerna launched in January 2022 with a $100 million Series A backed by Third Rock Ventures. The company is headquartered at 250 East Grand Avenue, South San Francisco, CA.

Summary

Septerna is a Biotech company based in South San Francisco, United States, founded in 2022. It has raised $250.0M in total across 2 rounds, most recently a $150.0M Series B round in Jul 2023. Investors include Third Rock Ventures, RA Capital Management and Samsara BioCapital.

Tech & App Stack

8 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

IPOOct 2024
$288.0M

Sign up to see all 3 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Septerna on Indexed.vc
<a href="https://indexed.vc/companies/septerna"><img src="https://indexed.vc/api/badge/company/septerna" alt="Septerna on Indexed.vc" width="260" height="76" /></a>